Advanced glycosylation end products (AGEs) have been implicated in the pathogenesis of diabetic complications. Treatment of RAW 264.7 macrophages with bovine serum albumin (BSA)-derived AGEs caused dose- and time-dependent increases in nitrite production and inducible nitric oxide synthase (iNOS) expression. These effects were blocked by the nuclear factor-kappa B (NF-κB) inhibitor, pyrrolidone dithiocarbamate (PDTC). BSA-AGEs also stimulated the translocation of p65 NF-κB from cytosol to the nucleus. Electrophoretic mobility shift assay revealed that the NF-κB DNA-protein-binding activity was enhanced by AGEs. The tyrosine kinase inhibitor, genistein, the phosphatidylinositol-3-kinase (PI 3-K) inhibitor, LY 294002, the protein kinase C (PKC) inhibitor, Ro 31-8220, and the p38 mitogen-activated protein kinase (MAPK) inhibitor, SB 203580, all inhibited AGEs-stimulated iNOS expression, NO release, NF-κB translocation and NF-κB DNA binding activity. These results suggest that AGEs may activate NF-κB via an upstream signaling cascade composed of tyrosine kinase, PI 3-K, PKC, and p38 MAPK, resulting in the induction of iNOS expression in RAW 264.7 macrophages.

Original languageEnglish
Pages (from-to)9-17
Number of pages9
JournalMolecular and Cellular Endocrinology
Issue number1-2
Publication statusPublished - Aug 30 2002


  • Advanced glycosylation end products
  • Inducible nitric oxide synthase
  • Nuclear factor-kappa B
  • RAW 264.7 macrophages

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Endocrinology


Dive into the research topics of 'Advanced glycosylation end products induce NF-κB dependent iNOS expression in RAW 264.7 cells'. Together they form a unique fingerprint.

Cite this